INDV: Indivior plc Market Cap to Revenue Ratio

Symbol and logo of brand Indivior Group (INDV)

Indivior PLC dominates opioid addiction therapy through Sublocade, extracting superprofits from inelastic demand. The market cap-to-revenue ratio confirms this resilience, with the metric currently standing at 2.60. The company is building a comprehensive treatment environment by integrating medications with psychological support. The business is currently scaling long-acting injections while navigating legal complexities and generic pressure.

indivior.com (INDV): Market Cap to Revenue from 02/21/2024 to 11/13/2026

Metric breakdowns and analytics for Indivior Group (INDV)

- stock price and consensus target price:
Share Price indivior.com|INDV - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Indivior Group|INDV - Enterprise Value
- business book valuation details:
Net Assets per Share Indivior|INDV - Company Net Assets|Market Value to Book Value Ratio indivior.com|INDV - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Indivior PLC|INDV - Long-Term Debt to Equity|Current Liabilities to Capital Indivior Corp|INDV - Company Debts|Debt to Net Assets Ratio Indivior Group|INDV - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Indivior|Critical Liquidity Ratio indivior.com
- net income and valuation ratios data:
INDV - Company Net Income|Expected Profit Indivior PLC|INDV - P/E Multiple|Projected Price to Earnings Indivior plc|INDV - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Indivior Group|INDV - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Indivior|INDV - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months indivior.com|INDV - Net earnings per share growth this year|Net earnings per share growth forecast for next year Indivior PLC
- sales revenue and business income indicators:
INDV - Company Revenue|Company Revenue Forecast indivior.com|INDV - P/S Multiple|Forward P/S Multiple Indivior Group
Fundamental company analysis:indivior.com, INDV
Core merchandise of Indivior

Investors must evaluate the resilience of Indivior PLC to patent risks and the pace of portfolio diversification through the lens of the market value of one dollar of revenue. The current P/S multiple of 2.60 reflects the ratio of market capitalization to total sales, allowing for a determination of the asset's overvaluation relative to its actual ability to generate cash flow under intense legal pressure.

Who Indivior PLC competes with

collegiumpharma.com - Market Cap to Revenue Ratio|P/S Multiple CRON (Cronos Group)|CGC: Market Cap to Revenue Ratio|High Tide Corp - P/S Multiple|Price-to-Revenue Coefficient Aurora Cannabis ACB|ACHV (Achieve Life Sciences) - Market Cap to Revenue|SKYE (skyebioscience.com) - Price-to-Revenue Ratio|ANEB (Anebulo Pharmaceuticals, Inc.) - P/S Multiple|Canndoc (INCR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nutriband Inc. (NTRB)|NSRX - Price to Sales|Price-to-Revenue Ratio IGC Pharma IGC|Market Capitalization-to-Revenue Ratio MIRA|FLGC: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMCC (IM Cannabis Corp.)|adialpharma.com (ADIL) - Price-to-Revenue Ratio|Price-to-Sales Ratio ARTL (Artelo Biosciences, Inc.)|Price-to-Revenue Ratio Ensysce Biosciences Inc.|Price-to-Revenue Ratio TTNP|P/S Multiple GNLN|Market Cap to Revenue InMed Pharmaceuticals Inc INM|P/S Multiple AKAN (Akanda Corporation)|Price-to-Revenue Coefficient Enveric Corp (ENVB)|BGXX - Price-to-Revenue Ratio|HPCO (Hempacco Co Inc.) - Market Cap to Revenue Ratio